These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 33934105)

  • 1. Enhancer rewiring in tumors: an opportunity for therapeutic intervention.
    Richart L; Bidard FC; Margueron R
    Oncogene; 2021 May; 40(20):3475-3491. PubMed ID: 33934105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcriptional dysregulation by aberrant enhancer activation and rewiring in cancer.
    Okabe A; Kaneda A
    Cancer Sci; 2021 Jun; 112(6):2081-2088. PubMed ID: 33728716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of activated enhancers and linked transcription factors in breast, prostate, and kidney tumors by tracing enhancer networks using epigenetic traits.
    Rhie SK; Guo Y; Tak YG; Yao L; Shen H; Coetzee GA; Laird PW; Farnham PJ
    Epigenetics Chromatin; 2016; 9():50. PubMed ID: 27833659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancer RNAs in cancer: regulation, mechanisms and therapeutic potential.
    Lee JH; Xiong F; Li W
    RNA Biol; 2020 Nov; 17(11):1550-1559. PubMed ID: 31916476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The molecular understanding of super-enhancer dysregulation in cancer.
    Yoshino S; Suzuki HI
    Nagoya J Med Sci; 2022 May; 84(2):216-229. PubMed ID: 35967935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancer malfunction in cancer.
    Herz HM; Hu D; Shilatifard A
    Mol Cell; 2014 Mar; 53(6):859-66. PubMed ID: 24656127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multifaceted regulation of enhancers in cancer.
    Xiao Q; Xiao Y; Li LY; Chen MK; Wu M
    Biochim Biophys Acta Gene Regul Mech; 2022 Aug; 1865(6):194839. PubMed ID: 35750313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancer Features that Drive Formation of Transcriptional Condensates.
    Shrinivas K; Sabari BR; Coffey EL; Klein IA; Boija A; Zamudio AV; Schuijers J; Hannett NM; Sharp PA; Young RA; Chakraborty AK
    Mol Cell; 2019 Aug; 75(3):549-561.e7. PubMed ID: 31398323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Core regulatory circuitries in defining cancer cell identity across the malignant spectrum.
    Jahangiri L; Tsaprouni L; Trigg RM; Williams JA; Gkoutos GV; Turner SD; Pereira J
    Open Biol; 2020 Jul; 10(7):200121. PubMed ID: 32634370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging roles of and therapeutic strategies targeting BRD4 in cancer.
    White ME; Fenger JM; Carson WE
    Cell Immunol; 2019 Mar; 337():48-53. PubMed ID: 30832981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition.
    Rathert P; Roth M; Neumann T; Muerdter F; Roe JS; Muhar M; Deswal S; Cerny-Reiterer S; Peter B; Jude J; Hoffmann T; Boryń ŁM; Axelsson E; Schweifer N; Tontsch-Grunt U; Dow LE; Gianni D; Pearson M; Valent P; Stark A; Kraut N; Vakoc CR; Zuber J
    Nature; 2015 Sep; 525(7570):543-547. PubMed ID: 26367798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptional enhancers: from prediction to functional assessment on a genome-wide scale.
    Tobias IC; Abatti LE; Moorthy SD; Mullany S; Taylor T; Khader N; Filice MA; Mitchell JA
    Genome; 2021 Apr; 64(4):426-448. PubMed ID: 32961076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential cofactor dependencies define distinct types of human enhancers.
    Neumayr C; Haberle V; Serebreni L; Karner K; Hendy O; Boija A; Henninger JE; Li CH; Stejskal K; Lin G; Bergauer K; Pagani M; Rath M; Mechtler K; Arnold CD; Stark A
    Nature; 2022 Jun; 606(7913):406-413. PubMed ID: 35650434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissecting super-enhancer driven transcriptional dependencies reveals novel therapeutic strategies and targets for group 3 subtype medulloblastoma.
    Li M; Han Y; Wang C; Kang W; Jiang W; Zhang L; Tang Y
    J Exp Clin Cancer Res; 2022 Oct; 41(1):311. PubMed ID: 36273157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Control of p53-dependent transcription and enhancer activity by the p53 family member p63.
    Karsli Uzunbas G; Ahmed F; Sammons MA
    J Biol Chem; 2019 Jul; 294(27):10720-10736. PubMed ID: 31113863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
    Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
    Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancer RNA: What we know and what we can achieve.
    Han Z; Li W
    Cell Prolif; 2022 Apr; 55(4):e13202. PubMed ID: 35170113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancer identification in mouse embryonic stem cells using integrative modeling of chromatin and genomic features.
    Chen CY; Morris Q; Mitchell JA
    BMC Genomics; 2012 Apr; 13():152. PubMed ID: 22537144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating Enhancer Function and Transcription.
    Field A; Adelman K
    Annu Rev Biochem; 2020 Jun; 89():213-234. PubMed ID: 32197056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Super-enhancers in cancer.
    Thandapani P
    Pharmacol Ther; 2019 Jul; 199():129-138. PubMed ID: 30885876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.